Latest News in the pharma Industry

Research & Development

Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity

Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity

16 Aug 2017

Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.

Read more 
Regeneron to discontinue development of suptavumab for respiratory syncytial virus

Regeneron to discontinue development of suptavumab for respiratory syncytial virus

14 Aug 2017

Phase III study fails to meet its primary endpoint.

Read more 
Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline

Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline

14 Aug 2017

Inotersen on track for marketing authorization filings this year.

Read more 
Fortress Biotech forms new subsidiary, Aevitas Therapeutics

Fortress Biotech forms new subsidiary, Aevitas Therapeutics

14 Aug 2017

Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.

Read more 
Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

14 Aug 2017

The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.

Read more 
FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

14 Aug 2017

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Read more 
Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

13 Aug 2017

NIH-led clinical trial suggests that drug slows progression of rare neurological disease.

Read more 
Major progress in next generation medicines initiative

Major progress in next generation medicines initiative

10 Aug 2017

Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.

Read more 
NCI study identifies essential genes for cancer immunotherapy

NCI study identifies essential genes for cancer immunotherapy

7 Aug 2017

This knowledge could speed the development of a new category of drugs.

Read more 
AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

6 Aug 2017

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

Read more 
IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

3 Aug 2017

The launch represents a major step towards therapeutic use of CRISPR.

Read more 
BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

3 Aug 2017

Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read more